Novel anthranilic acid derivatives having substituted N-acyl side chains were designed and synthesized for evaluation as plasminogen activator inhibitor-1 (PAI-1) inhibitors. Compounds with a 4-diphenylmethyl-1-piperazinyl moiety on the acyl side chains in general exhibited potent in vitro PAI-1 inhibitory activity and good pharmacokinetic profiles after oral administration in rats. Compound 16f (TM5275) was identified as a promising candidate for further pharmacological evaluation.
Elevated levels of plasminogen activator inhibitor-1 (PAI-1), a serine protease which inhibits tissue-type and urokinase-type plasminogen activators (tPA and uPA, respectively), is thought to be a cause of a variety of diseases, 1) such as thrombotic diseases (e.g., brain infarction, deep vein thrombosis, etc.), tissue fibrotic diseases (e.g., lung thrombosis, renal thrombosis, liver thrombosis etc.), arteriosclerosis, obesity and cancer, due to insufficient activation of a proteolytic enzyme plasmin. Furthermore, recent reports suggest that PAI-1 inhibitors may be useful to treat Alzheimer's disease, 2) glaucoma, 3) and retinopathy. 4) Thus, a number of synthetic small molecule PAI-1 inhibitors, e.g., PAI-039 (tiplaxtinin), 5) PAI-749 (diaplasinin), 6) PAZ-417 2) have been reported to date targeted towards the development of new drugs to modify above-mentioned diseases, although the clinical benefits of these inhibitors are still not known.
We have also previously reported novel PAI-1 inhibitors TM5001, 7) TM5007 7) and their related compounds such as 1 and 2 8) ( Fig. 1 ) with an acylaminothiophene-carboxylic acid dimer structure to which lipophilic or/and bulky groups are attached as the aromatic ring substituents. Although these compounds had potent in vitro PAI-1 inhibitory activity, they exhibited rather undesirable pharmacokinetic (PK) property (e.g., slow and insufficient absorption, too long duration of the plasma level) when administered orally; plasma C max , T max and T 1/2 were 32 mM, 18 h, and 54 h for TM5001, 7) 5.8 mM, 18 h, and Ͼ174 h for 1, 2.32 mM, 48 h, and >48 h for 2, respectively, in rats given 50 mg/kg. We therefore continued our search to identify compounds with both potent PAI-1 inhibitory activity and improved oral PK profiles by designing more drug-like structures than the previously reported thiophene dimers (TM5001, 1, 2). Our major efforts were directed toward the syntheses of novel compounds without the dimer structure, possessing as low molecular weight as possible, and with lower ClogP 9) compared to those of TM5001 (5.79), 1 (5.32) and 2 (7.06).
One of the most important findings in the thiophene dimer series which we have reported was that the dicarboxyl compound 1 and the corresponding mono-ester compound 2 were almost equipotent in in vitro PAI-1 inhibition, suggesting that the symmetrical dimer structure was not always necessary and one carboxyl moiety was sufficient to elicit PAI-1 inhibitory property. 8) Based upon these findings, we investigated further structure-optimization as briefly illustrated in Fig. 2 . This paper describes structure-activity relationship (SAR) studies to identify a novel PAI-1 inhibitor, TM5275 10) ( Fig. 3) as an orally bioavailable, promising drug candidate.
Chemistry General synthetic routes to various novel target compounds are outlined in Charts 1 and 2.
N-Acylanthranilic acid derivatives (8a, a, 13) were first prepared as shown in Chart 1 in order to demonstrate if one or both of the thiophene rings of the lead compounds, TM5001, 1 and 2 could be converted to the possibly bioisosteric benzene ring(s). tert-Butyl 2-amino-4-phenylthiophene-3-carboxylate (3) and p-chloroaniline (9) were acylated with methyl adipoyl chloride, followed by alkaline hydrolysis to obtain the corresponding adipic acid mono-amide derivatives 5 and 11, respectively. Compounds 5 and 11 were condensed with the methyl anthranilates (6a, a) to afford 7a, a and 12, which were then hydrolyzed to furnish N-acylanthranilic acid 216 Vol. 59, No. 2 (Fig. 2) . The ester-carboxylic acids (14) were prepared from 6 by reaction with the corresponding acid anhydrides. Then compounds 14 were condensed with hydrophobic amines (R 5 H) via the acid chlorides or the activated esters to give the corresponding amides (15).
Compounds 15 where R 4 ϭBr were successfully converted to the alkyl-, aralkyl-or aryl-substituted anthranilic acid ester derivatives (17) under Suzuki-Miyaura or Negishi cross-coupling reaction conditions. 11, 12) The target N-acylanthranilic acid derivatives (16a-q, 18a-d, Table 2 ) were obtained from these esters (15, 17) by alkaline hydrolysis in good yields.
The N-methyl derivative of 16f was also prepared to investigate the effect of the N-hydrogen atom at this position on the PAI-1 inhibitory activity. Methylation of 15f with methyl iodide in the presence of sodium hydride followed by hydrolysis furnished 20.
Results and Discussion
PAI-1 inhibitory activities of newly synthesized compounds are shown in Tables 1 and 2 together with those of previously reported compounds (TM5001, 1, 2). The in vitro PAI-1 activity is expressed as the remaining activity in percent (%) after incubation of PAI-1 with test compounds as described in the experimental section. Method A and Method B differ with the relative molar ratio of PAI-1 and tPA added to the medium (Method A; tPA : PAI-1ϭ1 : 6.9, Method B; tPA : PAI-1ϭ1 : 2.5). Method B provides a more sensitive assay than Method A to evaluate the PAI-1 activity at lower concentrations.
The biological property of compounds with a benzoic acid moiety in place of a thiophene-carboxylic acid structure in the compound 2 was first evaluated utilizing compounds 8a, a (Table 1) . Although compound 8a without any substituent on the benzene ring showed considerably decreased PAI-1 inhibitory activity, 8a with a chlorobenzoic acid structure showed activity comparable to TM5001. The results obtained here suggest that a phenyl-substituted thiophene-carboxylic acid moiety as in 2 can be replaced by a chlorobenzoic acid moiety without significant loss of activity. In addition, it was to be noted that compound 13 possessing anthranilic acid structure with an anilide moiety retained PAI-1 inhibitory property comparable to 8a, despite the facts that no thiophene ring was incorporated in the molecule of 13, and there was a considerable difference between the ClogP values of the two compounds 8a and 13. While appropriate lipophilic or/and bulky substituents may be necessary for these compounds to elicit potent in vitro effects, as reported previously, 8) ClogP value of the whole molecule does not seem to affect much the activity. However, it was considered worthwhile to decrease ClogP to improve oral PK profile of this series.
Based upon these observations and concepts, our efforts were then focused, as shown in Table 2 , on the syntheses of compounds possessing a substituted-anthranilic acid structure as A part illustrated in Fig. 2 , with a variety of hydrophobic amide moieties R 5 on the other end (B part) of the molecule and with different linkers L, taking ClogP of the molecule in consideration as well.
Next we focused on the structure-activity relationships (SAR) of the B part (Fig. 2, Table 2 ). While substituents such as diphenylamino (16b), 1,1-diphenylmethylamino (16c), and 4-phenyl-1-piperidinyl group (16d) were not satisfactory to potentiate the activity, compounds with 4,4-diphenyl-1-piperidinyl (16e) and 4-(diphenylmethyl)-1-piperazinyl groups (16f) showed activities superior to 16a. Although there was little difference between 16e and 16f in in vitro activity, we decided to concentrate in 16f type of compounds, because 16f showed a smaller ClogP and a better PK profile than 16e, and also diphenylmethylpiperazinyl derivatives could be prepared relatively easily compared to diphenylpiperidinyl ones. Introduction of N-bis(4-fluorophenyl)-methyl (16g) and N-9H-fluorenyl (16h) substituents in piperazine moiety also resulted in a slight decrease in the in vitro activity compared to 16f. Therefore, we fixed the B part ( Fig.  2) as the 4-diphenylmethyl-1-piperazinyl group to conduct further SAR studies.
The positions of the substituents on the benzoic acid moiety (A part) were evaluated with compounds 16i-18d. Although introduction of a fluorine atom to the 5-position resulted in a slight decrease in activity, compounds with bulkier or more hydrophobic substituents such as bromine atom (16j), isopropyl (18a) and benzyl (18b) groups tended to retain the activity. 4-Bromo, 5-(3-pyridyl) and 4-(4-pyridyl) derivatives (16k, 18c, 18d) also exhibited potent inhibitory activity. The difference in the position of these substituents (4-or 5-position) did not seem to significantly affect the potency of in vitro activity, suggesting that steric bulkiness adjacent to the phenyl ring appears to be more important than the position of the substitution as has been observed with the thiophene-carboxylic acid series. 8) Variation of the linker L by introducing a methylene group, sulfur and nitrogen atoms as X (Fig. 2) as in 16n-16q ( ND ND ND drastic loss in activity indicating that the NH group at this position seems to play a very important role in the N-acylanthranilic acid derivatives to elicit potent PAI-1 inhibitory activity (Table 2) . In order to identify a good orally-bioavailable compound for further in vivo studies, pharmacokinetic (PK) profiles of the representative compounds were compared in rats by oral administration (Table 2 ; see Experimental in detail). Although no direct correlation was seen between ClogP and PK, compounds showing good PK had ClogPϽ5.0 as shown in Table 2 . Compounds 18c and 18d with a pyridyl group at the 4-or 5-position had a low ClogP (3.06) but exhibited only poor PK profiles, while the reason is not known at present. From these results compound 16f (TM5275) 10) possessing both potent in vitro PAI-1 inhibitory activity and a good PK profile, e.g., high maximum plasma concentration (C max ), was selected as a candidate for future development.
Conclusion
Based upon the basic structure of 2-acylamino-3-thiophenecarboxylic acids (TM5001, 1, 2) which we have previously reported, 7, 8) novel N-acylanthranilic acid derivatives, in particular N-acyl-5-chloroanthranilic acid derivatives were designed, synthesized and evaluated for in vitro PAI-1 inhibitory activity and oral PK profiles in rats. It was found that both PAI-1 inhibition and oral bioavailability were much improved when a 4-diphenylmethyl-1-piperazinyl group was introduced on the acyl side chain. Thus compound 16f (TM5275) 10) was finally identified as a promising candidate for further pharmacological evaluation.
TM5275 may provide not only a useful tool for a better understanding of the pathophysiology of PAI-1 but also a potential new treatment for diseases where PAI-1 has been implicated.
Experimental
General Melting points (mp) were determined on METTLER TOLEDO MP70 Melting Point Systems and are uncorrected. B at a flow rate of 0.8 ml/min. LC/MS spectra were recorded on an Alliance HPLC system using a ULTORON VX-ODS C 18 column (5 mm, 4.6ϫ150 mm i.d.) coupled with an micromass ZQ as MS detector in the mode of electrospray ionization (ESI) and a gradient of 5-100% B over 20 min was used with a flow rate of 1.0 ml/min. Formic acid 0.1% was added to solvents A and B (water (A) and MeCN (B)).
tert-Butyl 2-[(6-Methoxy-6-oxohexanoyl)amino]-4-phenylthiophene-3-carboxylate (4) Methyl adipoyl chloride (15.8 g, 88.2 mmol) was added to a solution of tert-butyl 2-amino-4-phenylthiophene-3-carboxylate (3) (24.3 g, 88.2 mmol) in dimethylacetamide (DMA) (70 ml) at 0°C, and the mixture was stirred at room temperature for 1 h. Aqueous NaHCO 3 solution was added to the reaction mixture and the resulting precipitate was collected by suction filtration, washed with water and n-hexane, and dried in vacuo to afford 30.3 g (yield 82%) of 4 as a solid, (THF) (100 ml) was added 1 N aqueous NaOH solution (104 ml) and the mixture was stirred for 2.5 h at 60°C. After evaporation of organic solvent, the aqueous solution was washed with ethyl acetate (EtOAc). After 1 N aqueous HCl was added to the aqueous solution, the mixture was extracted with EtOAc three times. The combined organic layers were washed with brine, dried (Na 2 SO 4 ), and concentrated in vacuo. The residue was purified by recrystallization from EtOAc/n-hexane to afford 20. 47 mmol) and Et 3 N (326 mg, 3.22 mmol) in THF (9 ml) was added methanesulfonyl chloride (369 mg, 322 mmol) at 0°C and the mixture was stirred for 1 h. A solution of methyl anthranilate (6a) (487 mg, 3.22 mmol) in THF (1 ml) was added to the reaction mixture at 0°C. The mixture was stirred at room temperature for 16 h. Water was added to the reaction mixture and the whole mixture was extracted with EtOAc three times. The combined organic layers were washed with brine, dried (Na 2 SO 4 ) and concentrated in vacuo. The residue was purified by column chromatography on silica gel (acetone/n-hexane 1/5) to afford 730 mg (yield 55%) of 7a as a solid, 
Methyl 6-[(4-Chlorophenyl)amino]-6-oxohexanoate (10)
Methyl adipoyl chloride (8.6 g, 48 mmol) was added to a solution of 4-chloroaniline (9) (6.7 g, 53 mmol) in DMA at 0°C, and the mixture was stirred at room temperature for 17 h. Aqueous NaHCO 3 solution was added to the reaction mixture and the resulting precipitate was collected by filtration, washed with water and IPE, and dried in vacuo to afford 11.0 g (yield 85%) of 10 as a solid, (
2-{[3-(Methoxycarbonyl)biphenyl-4-yl]amino}-2-oxoethoxy)acetic Acid (14d)
This compound was prepared in 89% yield as a solid from methyl 4-aminobiphenyl-3-carboxylate (6d) 13) and diglycolic anhydride following a procedure similar to that described for the preparation of 14a, 1 1 (1H, s), 12.7 (1H, br) .
[(2-{[4-Chloro-2-(methoxycarbonyl)phenyl]amino}-2-oxoethyl)-(methyl)amino]acetic Acid (14i) A mixture of N-methyliminodiacetic acid (3.2 g, 21.5 mmol) and acetic anhydride (16 ml) was refluxed for 0.5 h. After evaporation of acetic anhydride, a solution of 6a (4.0 g, 21.6 mmol) in THF (20 ml) was added to this residue and the mixture was refluxed for 1.5 h. After evaporation of organic solvent, the residue was purified by column chromatography on silica gel (CHCl 3 /methanol (MeOH)ϭ5/1) to afford 5.0 g (yield 73%) of 14i as a solid, 
Methyl 5-Chloro-2-[({2-[(4-chlorophenyl)amino]-2-oxoethoxy}acetyl)-amino]benzoate (15a)
To a mixture of 14a (500 mg 1.66 mmol) and N,Ndimethylformamide (DMF) (cat. amount) in THF (5 ml) was added oxalyl dichloride (414 mg,1.99 mmol) at 0°C, and the mixture was stirred at room temperature for 1 h. After evaporation of organic solvent, a solution of 4-chloroaniline (211 mg, 1.66 mmol) in DMA (5 ml) was added to the residue at 0°C, and the mixture was stirred at room temperature for 1 h. Aqueous NaHCO 3 solution was added to the reaction mixture and the resulting precipitate was collected by suction filtration and washed with water to afford 345 mg (yield 51%) of 15a as a solid, 1 1H, s) .
Methyl 5-Chloro-2-({[2-(diphenylamino)-2-oxoethoxy]acetyl}amino)-benzoate (15b)
To a mixture of 14a (1.0 g, 3.31 mmol) and DMF (cat. amount) in THF (10 ml) was added oxalyl dichloride (505 mg, 3.98 mmol) at 0°C, and the mixture was stirred at room temperature for 1 h. After evaporation of organic solvent, a solution of diphenylamine (617 mg, 3.65 mmol) in DMA (10 ml) was added to the residue at 0°C, and the mixture was stirred at room temperature for 1.5 h. Aqueous NaHCO 3 solution was added to the reaction mixture and the solution was extracted with EtOAc three times. The combined organic layers were washed with brine, dried (Na 2 SO 4 ) and concentrated in vacuo. The residue was purified by column chromatography on silica gel (EtOAc/n-hexaneϭ1/1) to afford 717 mg (yield 48%) of 15b as a solid, 
Methyl 5-Chloro-2-[({2-[(diphenylmethyl)amino]-2-oxoethoxy}acetyl)-amino]benzoate (15c)
To a mixture of 14a (0.81 g, 2.68 mmol) and DMF (cat. amount) in THF (15 ml) was added oxalyl dichloride (411 mg, 3.24 mmol) at 0°C, and the mixture was stirred at room temperature for 1 h. After evaporation of organic solvent, a solution of benzhydrylamine (594 mg, 3.24 mmol) in DMA (15 ml) was added to the residue at 0°C, and the mixture was stirred at room temperature for 14 h. Aqueous NaHCO 3 solution was added to the reaction mixture and the solution was extracted with EtOAc three times. The combined organic layers were washed with brine, dried (Na 2 SO 4 ) and concentrated in vacuo. IPE was added to the residue and the resulting crystal was collected by filtration, and dried in vacuo to afford 610 mg (yield 49%) of 15c as a solid, 
Methyl 5-Chloro-2-({[2-(4,4-diphenylpiperidin-1-yl)-2-oxoethoxy]-acetyl}amino)benzoate (15e)
To a mixture of 14a (1.0 g, 3.31 mmol) and DMF (cat. amount) in THF (20 ml) was added oxalyl dichloride (505 mg, 3.98 mmol) at 0°C, and the mixture was stirred at room temperature for 1 h. After evaporation of organic solvent, a mixture of 4,4-diphenylpiperidine hydrochloride (998 mg, 3.65 mg) and Et 3 N (369 mg, 3.65 mmol) in DMA (20 ml) was added to the residue at 0°C, and the mixture was stirred at room temperature for 1.5 h. Aqueous NaHCO 3 solution was added to the reaction mixture and the solution was extracted with EtOAc three times. The combined organic layers were washed with brine, dried (Na 2 SO 4 ) and concentrated in vacuo. The residue was purified by column chromatography on silica gel (EtOAc/n-hexaneϭ1/1) to afford 850 mg (yield 49%) of 15e as a solid, 6 mmol) in DMA (28 ml) were added 1-benzhydrylpiperazine (2.93 g, 11.6 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSC) (2.67 g, 13.9 mmol) and 1-hydroxy-1H-benzotriazole (HOBt) (1.88 g, 13.9 mmol) at 0°C, and the mixture was stirred at room temperature for 2 h. Aqueous NaHCO 3 solution was added to the reaction mixture and the resulting precipitate was collected by filtration and washed with water to afford 'quantitative' yield of 15k as a solid, 
Sodium 5-Chloro-2-({[2-(diphenylamino)-2-oxoethoxy]acetyl}amino)-benzoate (16b)
To a solution of 15b (717 mg, 1.6 mmol) in THF (13 ml) was added 1 N aqueous NaOH solution (4.3 ml) and the mixture was stirred at 60°C for 7 h. After cooling and evaporation of THF in vacuo, the resulting precipitate was collected by suction filtration and washed with water to give a crude product which was recrystallized from a mixed solvent of MeOH and water to afford 508 mg (yield 70%) of 16b as a solid, mp Ͼ300°C (MeOH/H 2 O), 
2-{[(2-{4-[Bis(4-fluorophenyl)methyl]piperazin-1-yl}-2-oxoethoxy)-acetyl]amino}-5-chlorobenzoic Acid (16g)
To a solution of 15g (1.47 g, 2.56 mmol) in THF (26 ml) was added 1 N aqueous NaOH solution (3.8 ml) and the mixture was stirred at 60°C for 1 h. The reaction solution was neutralized with 1 N aqueous HCl solution and the organic solvent was removed in vacuo. The resulting precipitate was collected by filtration and washed with water and IPE, and dried in vacuo to afford 1.33 g (yield 93%) of 16g as an amorphous solid,
